Motley Fool Asset Management LLC Buys 29,394 Shares of Gilead Sciences, Inc. $GILD

Motley Fool Asset Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 131,295 shares of the biopharmaceutical company’s stock after buying an additional 29,394 shares during the period. Motley Fool Asset Management LLC’s holdings in Gilead Sciences were worth $16,115,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $28,000. Financial Consulate Inc. boosted its position in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 109 shares during the last quarter. North Star Investment Management Corp. boosted its position in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 86 shares during the last quarter. BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $31,000. Finally, Godfrey Financial Associates Inc. purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $34,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 68,000 shares of company stock valued at $9,047,570. Insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Down 2.0%

Shares of NASDAQ:GILD opened at $125.50 on Wednesday. The stock has a market capitalization of $155.82 billion, a price-to-earnings ratio of 17.10 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock’s 50-day simple moving average is $134.03 and its two-hundred day simple moving average is $134.37. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the firm posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Bank of America set a $162.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, February 11th. Leerink Partners dropped their price objective on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Mizuho increased their price objective on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Wednesday, May 20th. Finally, Scotiabank increased their price objective on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 11th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $156.93.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive Phase 3 results for their once-weekly oral HIV regimen, islatravir/lenacapavir, meeting the primary efficacy endpoint in both ISLEND trials. This is important because it supports Gilead’s HIV franchise, which is a major driver of the company’s business. Article Title
• Positive Sentiment: Analysts and media coverage highlighted that the successful once-weekly HIV tablet could strengthen Gilead’s core growth outlook, since a more convenient regimen may help expand or defend market share in HIV treatment. Article Title
• Neutral Sentiment: Gilead and Merck also discontinued a Phase 3 lung cancer study of Trodelvy plus Keytruda after it failed to show a statistically significant progression-free survival benefit. The trial stop is disappointing, but it mainly affects Gilead’s oncology ambitions rather than its larger HIV business. Article Title
• Neutral Sentiment: RBC noted a potential longer-term competitive threat from in vivo CAR-T technology, but this looks more like an early-stage strategic risk than a near-term catalyst for the stock. Article Title
• Negative Sentiment: At least one report characterized the news as mixed because the HIV win was partially offset by the Trodelvy setback, which may temper investor enthusiasm for Gilead’s broader pipeline. Article Title

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.